ICYMI: Exa-cel for Beta Thalassemia, Sickle Cell Disease Accepted for Priority Review by Health Canada
Source: www.pixabay.com

ICYMI: Exa-cel for Beta Thalassemia, Sickle Cell Disease Accepted for Priority Review by Health Canada

On December 13, 1996, Health Canada issued a policy statement called Priority Review of Drug Submissions which: provided for the "fast-tracking" of eligible New Drug Submissions (NDS) and Supplemental New…

Continue Reading ICYMI: Exa-cel for Beta Thalassemia, Sickle Cell Disease Accepted for Priority Review by Health Canada
Rare Community Profiles: How Two Parents Are Working to Change the Narrative Around CASK Gene Disorder
Fotocitizen / Pixabay

Rare Community Profiles: How Two Parents Are Working to Change the Narrative Around CASK Gene Disorder

  Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Continue Reading Rare Community Profiles: How Two Parents Are Working to Change the Narrative Around CASK Gene Disorder